↓ Skip to main content

Hereditary Tyrosinemia

Overview of attention for book
Cover of 'Hereditary Tyrosinemia'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Discovery of Hereditary Tyrosinemia in Saguenay- Lac St-Jean
  3. Altmetric Badge
    Chapter 2 Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1
  4. Altmetric Badge
    Chapter 3 Molecular Aspects of the FAH Mutations Involved in HT1 Disease
  5. Altmetric Badge
    Chapter 4 Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1
  6. Altmetric Badge
    Chapter 5 Tyrosinemia and Liver Transplantation: Experience at CHU Sainte-Justine
  7. Altmetric Badge
    Chapter 6 The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec
  8. Altmetric Badge
    Chapter 7 Liver Transplantation for Hereditary Tyrosinaemia Type 1 in the United Kingdom
  9. Altmetric Badge
    Chapter 8 NTBC and Correction of Renal Dysfunction
  10. Altmetric Badge
    Chapter 9 Liver Cancer in Tyrosinemia Type 1
  11. Altmetric Badge
    Chapter 10 Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients
  12. Altmetric Badge
    Chapter 11 Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening
  13. Altmetric Badge
    Chapter 12 Tyrosinemia Type I in Japan: A Report of Five Cases
  14. Altmetric Badge
    Chapter 13 Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update
  15. Altmetric Badge
    Chapter 14 Hepatorenal Tyrosinemia in Mexico: A Call to Action
  16. Altmetric Badge
    Chapter 15 Hereditary Tyrosinemia Type 1 in Turkey
  17. Altmetric Badge
    Chapter 16 From Weed Killer to Wonder Drug
  18. Altmetric Badge
    Chapter 17 The Québec NTBC Study
  19. Altmetric Badge
    Chapter 18 Dietary Considerations in Tyrosinemia Type I
  20. Altmetric Badge
    Chapter 19 Remaining Challenges in the Treatment of Tyrosinemia from the Clinician’s Viewpoint
  21. Altmetric Badge
    Chapter 20 Fah Knockout Animals as Models for Therapeutic Liver Repopulation
  22. Altmetric Badge
    Chapter 21 Gene Therapy in Tyrosinemia: Potential and Pitfalls
Attention for Chapter 13: Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update
Chapter number 13
Book title
Hereditary Tyrosinemia
Published in
Advances in experimental medicine and biology, January 2017
DOI 10.1007/978-3-319-55780-9_13
Pubmed ID
Book ISBNs
978-3-31-955779-3, 978-3-31-955780-9
Authors

Yves Giguère, Marie-Thérèse Berthier

Abstract

Hereditary tyrosinemia type I (HTI) is a rare autosomal recessive disorder caused by a fumarylacetoacetate hydrolase (FAH) deficiency. If untreated, its acute form is characterized by hepatic failure, renal dysfunction and neurological crisis, and may lead to death. Due to a genetic founder effect in the French-Canadian population, the prevalence of HTI is increased in the province of Quebec (1/19 819), with the IVS12 + 5G>A (1062 + 5G>A) splice site mutation responsible for more than 90% of mutated alleles. Universal newborn screening for (HT1) was thus established in 1970, and close to four million infants have been tested so far, allowing to identify 185 of the 190 affected newborns. During the 1970-1997 period, 2,249,000 newborns were screened at 3-7 days of life on dried filter paper blood spots by tyrosine (Tyr) concentration followed by indirect colorimetric semi-quantitative and quantitative (Q) succinylacetone (SA) testing (red blood cells δ-aminolevulinate dehydratase inhibition), with immunoreactive FAH as the confirmatory test. This approach allowed to identify 118 of 123 affected newborns. In 1998, owing to earlier hospital discharge and increased rate of breastfeeding, four cases were missed within the same year as the discriminating power of blood Tyr became inadequate. Thus, the screening algorithm was modified: indirect semi-quantitative SA measurement became the first-tier test between 1998 and 2014, and direct SA measurement by tandem mass spectrometry (MS/MS) was implemented in 2014, followed by indirect quantitative SA measurement as second tier test. Confirmation is performed by plasmatic amino acid profile and molecular testing. During the 1998-2016 period, more than 1,5 million neonates have been tested (90% sampled between 24 and 48 h of life): 67 of the 67 HTI cases were identified. Both indirect and direct SA measurement as the initial HTI screening test proved to be highly sensitive and specific, with positive and negative predicting value of 79% and 100% respectively.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 20%
Student > Master 4 13%
Researcher 3 10%
Professor 1 3%
Unspecified 1 3%
Other 2 7%
Unknown 13 43%
Readers by discipline Count As %
Medicine and Dentistry 6 20%
Pharmacology, Toxicology and Pharmaceutical Science 3 10%
Agricultural and Biological Sciences 2 7%
Biochemistry, Genetics and Molecular Biology 1 3%
Nursing and Health Professions 1 3%
Other 4 13%
Unknown 13 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2017.
All research outputs
#20,441,465
of 22,996,001 outputs
Outputs from Advances in experimental medicine and biology
#3,985
of 4,960 outputs
Outputs of similar age
#356,122
of 421,191 outputs
Outputs of similar age from Advances in experimental medicine and biology
#414
of 490 outputs
Altmetric has tracked 22,996,001 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,960 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,191 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 490 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.